PFE (Pfizer) How high will it go? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go?

PFE 25.09

+0.2%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JEB who wrote (6626)	1/5/1999 9:55:00 AM
From: BigKNY3	Read Replies (3) of 9523

Merrill Lynch PFE Update 1/4/99 Investment Highlights: · The label for Monsanto's Celebrex appears to be a good one with clear-cut differentiation versus other NSAIDs. · We continue to believe that Pfizer has the best fundamentals in the industry and should benefit from its co-promotion of Celebrex with Monsanto. Fundamental Highlights: · Everything we are looking for is in the label for Celebrex. The endoscopic data differentiating the product from existing NSAIDs is clearly laid out in the label. At six months, the data displays a lower rate of ulceration for Celebrex users versus users of other agents. This is a clear cut marketing hook to get into physicians' offices and to get them to use the product. · Other differentiating features include its lack of effect on platelets, its once-a-day indication for osteoarthritis, and what looks to be a milder gastrointestinal side-effect profile in abdominal pain, flatulence, and nausea. Its different mechanism of action is also laid out in the label.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next